Skip to main content

Table 4 Associations between TDP-43 and arteriolosclerosis (moderate/severe vs. none/mild) pathologies among included subjects stratified by APOE genotype

From: Dichotomous scoring of TDP-43 proteinopathy from specific brain regions in 27 academic research centers: associations with Alzheimer’s disease and cerebrovascular disease pathologies

Region

APOE −/− or −/ε4

(n = 679)a

APOE ε4/ε4

(n = 76)a

OR (95% CI)

P-value

OR (95% CI)

P-value

Model 1b

 Amygdala

1.66 (1.07–2.59)

0.023

0.71 (0.16–3.19)

0.65

 Hippocampus

1.40 (0.96–2.05)

0.083

0.89 (0.29–2.79)

0.84

 EC/inferior TCTX

1.82 (1.18–2.86)

0.0080

1.43 (0.35–6.55)

0.62

 Frontal neocortex

1.13 (0.50–2.61)

0.76

0.26 (0.01–3.04)

0.30

Model 2c

 Amygdala

1.43 (0.91–2.26)

0.12

0.57 (0.12–2.67)

0.47

 Hippocampus

1.19 (0.80–1.77)

0.39

0.80 (0.25–2.56)

0.70

 EC/inferior TCTX

1.60 (1.02–2.54)

0.041

1.13 (0.27–5.26)

0.87

 Frontal neocortex

1.08 (0.47–2.52)

0.86

0.21 (0.01–2.47)

0.23

  1. aA total of 755 subjects had data on APOE genotype (those data were missing in 174 subjects)
  2. bOdds ratios were adjusted for sex, age at death, and the type of TDP-43 antibody used
  3. cThal Aβ phase and Braak NFT stage were included as additional covariates in model 2
  4. OR odds ratio, CI confidence interval, EC entorhinal cortex, TCTX temporal cortex
  5. Bold p-value represents the statistical significance
Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us